MCID: VSC006
MIFTS: 51

Vascular Cancer malady

Categories: Cardiovascular diseases, Cancer diseases, Nephrological diseases, Blood diseases

Aliases & Classifications for Vascular Cancer

Aliases & Descriptions for Vascular Cancer:

Name: Vascular Cancer 12 14
Malignant Vascular Neoplasm 12 69
Renal Vein Leiomyosarcoma 12 69
Blood Vessel Tumors 12 52
Vascular Neoplasms 42 69
Malignant Tumor of Pulmonary Artery 12
Pulmonary Artery Malignant Neoplasm 12
Malignant Neoplasm of Great Vessels 69
Malignant Tumor of Pulmonary Vein 12
Pulmonary Vein Malignant Neoplasm 12
Leiomyosarcoma of the Renal Vein 12
Blood Vessel Tumour Disorder 12
Malignant Great Vessel Tumor 12
Neoplasms, Vascular Tissue 69
Malignant Vascular Tumor 12
Neoplasm of Great Vessel 12
Vascular Tissue Neoplasm 12
Haemangiomatous Tumour 12
Blood Vessel Neoplasm 12
Blood Vessel Cancer 69
Blood Vessel Tumor 12
Vascular Tumors 12

Classifications:



Summaries for Vascular Cancer

Disease Ontology : 12 A cardiovascular cancer that is located in blood vessels.

MalaCards based summary : Vascular Cancer, also known as malignant vascular neoplasm, is related to angiosarcoma and hemangioendothelioma. An important gene associated with Vascular Cancer is FLT4 (Fms Related Tyrosine Kinase 4), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Parecoxib and Sufentanil have been mentioned in the context of this disorder. Affiliated tissues include blood vessels, and related phenotypes are cardiovascular system and cellular

Related Diseases for Vascular Cancer

Diseases related to Vascular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 angiosarcoma 11.2
2 hemangioendothelioma 11.1
3 spindle cell hemangioma 11.1
4 hemangioma 11.0
5 breast angiosarcoma 10.7
6 glomeruloid hemangioma 10.7
7 carotid body cancer 10.6
8 intracranial cysts 10.3 FLT4 VEGFA
9 gapo syndrome 10.3 FLT4 KDR
10 eosinophilic pneumonia 10.3 FLT4 KDR
11 benign familial neonatal epilepsy 10.2 FLT4 KDR VEGFA
12 vasculogenic impotence 10.2 CAMTA1 HBA1
13 degenerative disc disease 10.2 VEGFA VWF
14 benign idiopathic neonatal seizures 10.2 FGF2 KDR VEGFA
15 hand, foot and mouth disease 10.2 KDR VEGFA
16 kidney osteogenic sarcoma 10.2 FLT1 KDR VEGFA
17 ovarian disease 10.2 FLT1 KDR VEGFA
18 aortic aneurysm 10.2 VEGFA VWF
19 vulvitis 10.2 FLT1 KDR VEGFA
20 arteriosclerosis obliterans 10.2 CD34 PDGFRB
21 albinism, oculocutaneous, type ib 10.2 FLT1 KDR VEGFA
22 multinodular goiter 10.2 KDR PDGFRB VEGFA
23 epidermolysis bullosa simplex, sutosomal recessive 2 10.2 FGF2 FLT1 VEGFA
24 craniosynostosis, type 1 10.2 THBS1 VEGFA
25 hemiplegic migraine 10.1 CAMTA1 FLI1 FLT4 KDR
26 intracranial hypotension 10.1 HBA1 KDR VEGFA
27 pleomorphic adenoma 10.1 CD34 HBA1
28 basophil adenoma 10.1 CD34 HBA1
29 welander distal myopathy 10.1 ENG FLT1 VEGFA
30 ovarian lymphoma 10.1 CD34 HBA1
31 obstructive jaundice 10.1 ENG FLT1 VEGFA
32 sarcocystosis 10.1 CD34 HBA1
33 arrhythmogenic right ventricular dysplasia 3 10.1 HBA1 KDR
34 metagonimiasis 10.1 FGF2 FLT4 KDR VEGFA
35 neuropathy with hearing impairment 10.1 CAMTA1 FLT1 KDR VEGFA
36 cervix endometrial stromal tumor 10.1 CD34 HBA1
37 vulvar dystrophy 10.1 CD34 HBA1
38 ovarian brenner tumor 10.1 FGF2 FLT4 KDR VEGFA
39 breast juvenile papillomatosis 10.1 CD34 HBA1
40 hemopneumothorax 10.1 CD34 HBA1
41 citrullinemia, type ii, neonatal-onset 10.1 FGF2 FLT1 KDR VEGFA
42 human venous malformation 10.1 ENG VEGFA VWF
43 superior vena cava angiosarcoma 10.1 CD34 HBA1
44 neuropathy, hereditary sensory, type ib 10.1 FGF2 KDR PDGFRB VEGFA
45 grade iii astrocytoma 10.1 FGF2 KDR PDGFRB VEGFA
46 bilateral breast cancer 10.1 CD34 HBA1
47 senile atrophy of choroid 10.1 CD34 VEGFA
48 phencyclidine abuse 10.0 CD34 FLT4 HBA1
49 thyroid angiosarcoma 10.0 CD34 HBA1 VEGFA
50 vesiculobullous skin disease 10.0 FLT4 HBA1 KDR VEGFA

Graphical network of the top 20 diseases related to Vascular Cancer:



Diseases related to Vascular Cancer

Symptoms & Phenotypes for Vascular Cancer

MGI Mouse Phenotypes related to Vascular Cancer:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 FLT4 KDR KIT PDGFRB THBS1 VEGFA
2 cellular MP:0005384 10.26 CD34 FGF2 FLI1 FLT1 KDR KIT
3 hematopoietic system MP:0005397 10.25 CD34 ENG FGF2 FLI1 FLT1 KDR
4 homeostasis/metabolism MP:0005376 10.24 ENG FGF2 FLT1 FLT4 KDR KIT
5 growth/size/body region MP:0005378 10.22 CAMTA1 ENG FLI1 FLT1 FLT4 KDR
6 immune system MP:0005387 10.18 KIT PDGFRB THBS1 VEGFA VWF CD34
7 mortality/aging MP:0010768 10.18 VEGFA VWF CAMTA1 ENG FGF2 FLI1
8 embryo MP:0005380 10.14 ENG FLI1 FLT1 FLT4 KDR KIT
9 digestive/alimentary MP:0005381 10.09 THBS1 VEGFA VWF ENG FLT4 KIT
10 muscle MP:0005369 10.07 ENG FGF2 FLI1 FLT1 FLT4 KDR
11 integument MP:0010771 10.06 CD34 ENG FLT4 KDR KIT PDGFRB
12 nervous system MP:0003631 9.96 ENG FGF2 FLI1 FLT1 KDR KIT
13 liver/biliary system MP:0005370 9.91 FLT4 KDR KIT THBS1 VEGFA FLI1
14 neoplasm MP:0002006 9.87 CAMTA1 CD34 FGF2 FLI1 KIT THBS1
15 normal MP:0002873 9.76 CAMTA1 ENG FLT1 FLT4 KDR KIT
16 reproductive system MP:0005389 9.56 CAMTA1 FGF2 FLT1 FLT4 KIT PDGFRB
17 vision/eye MP:0005391 9.17 FGF2 FLT1 KDR KIT PDGFRB THBS1

Drugs & Therapeutics for Vascular Cancer

Drugs for Vascular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1180)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Parecoxib Approved Phase 4 198470-84-7
2
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
3
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 347396-82-1 459903
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
5
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
6
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 9041-08-1
7
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 9005-49-6 772 46507594
8
Ethiodized oil Approved Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
9
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
10
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
11
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
12
Famotidine Approved Phase 4,Phase 2 76824-35-6 3325
13
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
14
Basiliximab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 152923-56-3, 179045-86-4
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
16
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
20
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
21
Amlodipine Approved Phase 4 88150-42-9 2162
22
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 79902-63-9 54454
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
25
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
26
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
28
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
29
Lisinopril Approved, Investigational Phase 4,Phase 2 83915-83-7 5362119
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
32
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
33
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
34
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
35
Bosentan Approved, Investigational Phase 4,Phase 2,Phase 1 147536-97-8 104865
36
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 525-66-6 4946
37
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
38
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
39
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
40
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
41
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 135968-09-1
42
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
43
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
44
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
45
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
46
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
47
Pancrelipase Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
48
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
49
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
50
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 4859)
id Name Status NCT ID Phase
1 Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
3 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4
4 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4
5 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4
6 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4
7 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4
8 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
9 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
10 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4
11 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4
12 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4
13 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
14 Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Unknown status NCT02184858 Phase 4
15 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
16 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4
17 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4
18 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
19 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4
20 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
21 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Completed NCT01908972 Phase 4
22 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
23 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
24 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
25 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4
26 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes Completed NCT01223196 Phase 4
27 A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction Completed NCT01561287 Phase 4
28 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4
29 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
30 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
31 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
32 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4
33 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
34 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4
35 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
36 Antinociceptive Modalities on Ischemia Reperfusion Injury Completed NCT01932918 Phase 4
37 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
38 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Completed NCT00081497 Phase 4
39 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4
40 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
41 LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
42 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4
43 Vascular Endothelial Protection Effects of Dextromethorphan Completed NCT00605605 Phase 4
44 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4
45 An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications Completed NCT02678676 Phase 4
46 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4
47 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
48 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
49 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
50 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4

Search NIH Clinical Center for Vascular Cancer

Cochrane evidence based reviews: vascular neoplasms

Genetic Tests for Vascular Cancer

Anatomical Context for Vascular Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Vascular Cancer:

18
Blood Vessels

Publications for Vascular Cancer

Articles related to Vascular Cancer:

id Title Authors Year
1
Research gives hope to patients with rare vascular cancer. Cleveland Clinic researchers suggest that their work could lead to breakthrough in treating other cancers. ( 22272406 )
2011
2
New strategies in anti-vascular cancer therapy. ( 10469169 )
1999
3
Anti-vascular cancer therapy: is it a dream or reality? ( 1720044 )
1991

Variations for Vascular Cancer

Expression for Vascular Cancer

Search GEO for disease gene expression data for Vascular Cancer.

Pathways for Vascular Cancer

Pathways related to Vascular Cancer according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 FGF2 FLT1 FLT4 KDR KIT PDGFRB
2
Show member pathways
13.31 FGF2 FLT1 FLT4 KDR KIT PDGFRB
3
Show member pathways
13.22 FGF2 FLT1 FLT4 KDR KIT PDGFRB
4
Show member pathways
13.2 FGF2 FLT1 FLT4 KDR KIT PDGFRB
5
Show member pathways
13.17 FGF2 FLT1 FLT4 KDR KIT PDGFRB
6
Show member pathways
12.99 FGF2 FLT1 FLT4 KDR KIT PDGFRB
7
Show member pathways
12.96 FGF2 FLT1 FLT4 KDR KIT PDGFRB
8
Show member pathways
12.9 FLT1 FLT4 KDR KIT PDGFRB
9
Show member pathways
12.88 FGF2 FLT1 FLT4 KDR KIT PDGFRB
10
Show member pathways
12.77 FLT1 FLT4 KDR PDGFRB THBS1 VEGFA
11
Show member pathways
12.59 FGF2 FLT1 FLT4 KDR
12 12.57 FGF2 KIT PDGFRB VEGFA
13
Show member pathways
12.42 FLT1 FLT4 KDR PDGFRB
14
Show member pathways
12.4 FGF2 FLT1 FLT4 KDR KIT PDGFRB
15
Show member pathways
12.37 FLT1 FLT4 KDR PDGFRB
16
Show member pathways
12.31 FLT1 FLT4 KDR VEGFA
17
Show member pathways
12.3 FGF2 FLT1 FLT4 KDR VEGFA
18 12.25 FGF2 KDR THBS1 VEGFA
19
Show member pathways
12.17 FGF2 FLT1 KDR VEGFA
20 12.14 FGF2 FLT1 FLT4 KDR KIT PDGFRB
21
Show member pathways
12.11 FLT1 FLT4 KDR PDGFRB
22
Show member pathways
12.03 KDR THBS1 VWF
23 11.99 FGF2 KDR PDGFRB VEGFA
24 11.91 CD34 ENG KIT
25
Show member pathways
11.91 FLT1 KDR PDGFRB VEGFA
26 11.89 FGF2 FLT1 FLT4 KDR KIT PDGFRB
27 11.79 CD34 ENG FGF2 KIT
28
Show member pathways
11.76 FLT1 FLT4 KDR VEGFA
29
Show member pathways
11.72 FLT1 FLT4 KDR KIT PDGFRB
30
Show member pathways
11.62 FLT1 FLT4 KDR KIT PDGFRB
31 11.53 FGF2 KDR KIT
32 11.49 FGF2 KDR VEGFA
33 11.47 FGF2 KIT VEGFA
34 11.44 FGF2 KDR VEGFA
35
Show member pathways
11.38 KDR PDGFRB VEGFA
36 11.27 FLT1 KDR VEGFA
37 11.16 ENG FGF2 FLT1 FLT4 KDR PDGFRB
38 11.13 FGF2 FLT1 VEGFA
39 11.11 FGF2 FLT1 KDR VEGFA
40
Show member pathways
10.83 FLT1 FLT4 KDR VEGFA

GO Terms for Vascular Cancer

Cellular components related to Vascular Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 ENG FGF2 FLT1 HBA1 KIT THBS1
2 external side of plasma membrane GO:0009897 9.62 CD34 ENG KIT THBS1
3 extracellular region GO:0005576 9.61 CD34 FGF2 FLT1 FLT4 HBA1 KDR
4 receptor complex GO:0043235 9.58 ENG FLT1 FLT4
5 platelet alpha granule GO:0031091 9.37 THBS1 VWF
6 platelet alpha granule lumen GO:0031093 9.33 THBS1 VEGFA VWF
7 cell surface GO:0009986 9.1 CD34 ENG KIT PDGFRB THBS1 VEGFA

Biological processes related to Vascular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.93 FGF2 KDR THBS1 VWF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 FGF2 FLT4 KDR PDGFRB
3 protein autophosphorylation GO:0046777 9.92 FLT1 FLT4 KDR KIT PDGFRB
4 positive regulation of protein phosphorylation GO:0001934 9.91 ENG FLT4 KDR VEGFA
5 angiogenesis GO:0001525 9.91 ENG FGF2 FLT1 FLT4 KDR VEGFA
6 regulation of cell shape GO:0008360 9.88 KDR KIT VEGFA
7 platelet degranulation GO:0002576 9.88 THBS1 VEGFA VWF
8 positive regulation of MAPK cascade GO:0043410 9.88 FLT1 FLT4 KDR KIT
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 FLT1 FLT4 KDR KIT PDGFRB
10 phosphatidylinositol-mediated signaling GO:0048015 9.87 FGF2 KIT PDGFRB
11 activation of MAPK activity GO:0000187 9.86 FGF2 KIT THBS1
12 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 FLT1 FLT4 KDR VEGFA
13 phosphatidylinositol phosphorylation GO:0046854 9.85 FGF2 KIT PDGFRB
14 positive regulation of endothelial cell proliferation GO:0001938 9.85 FGF2 FLT4 KDR VEGFA
15 positive regulation of cell migration GO:0030335 9.85 FLT1 KDR KIT PDGFRB THBS1 VEGFA
16 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.84 FGF2 KIT PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 FLT1 KDR KIT PDGFRB
18 vasculogenesis GO:0001570 9.81 ENG KDR VEGFA
19 positive regulation of endothelial cell migration GO:0010595 9.81 FLT4 KDR THBS1 VEGFA
20 peptidyl-tyrosine phosphorylation GO:0018108 9.8 FGF2 FLT1 FLT4 KDR KIT PDGFRB
21 sprouting angiogenesis GO:0002040 9.77 ENG FLT4 THBS1
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 FGF2 THBS1 VEGFA
23 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.76 FGF2 FLT1 KIT PDGFRB
24 positive regulation of cell proliferation GO:0008284 9.76 FGF2 FLT1 FLT4 KDR KIT PDGFRB
25 cell migration involved in sprouting angiogenesis GO:0002042 9.74 FGF2 KDR VEGFA
26 positive regulation of focal adhesion assembly GO:0051894 9.71 KDR VEGFA
27 artery morphogenesis GO:0048844 9.71 ENG VEGFA
28 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.71 FLT1 FLT4 KDR VEGFA
29 megakaryocyte development GO:0035855 9.7 FLI1 KIT
30 embryonic morphogenesis GO:0048598 9.7 FGF2 FLT1
31 embryonic hemopoiesis GO:0035162 9.7 KDR KIT
32 negative regulation of blood vessel endothelial cell migration GO:0043537 9.69 FGF2 THBS1
33 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 FLT1 VEGFA
34 positive regulation of chemotaxis GO:0050921 9.68 PDGFRB THBS1
35 positive regulation of positive chemotaxis GO:0050927 9.67 KDR VEGFA
36 positive regulation of vasculogenesis GO:2001214 9.67 CD34 KDR
37 vascular endothelial growth factor signaling pathway GO:0038084 9.67 FLT1 FLT4 KDR
38 stem cell proliferation GO:0072089 9.66 CD34 FGF2
39 positive regulation of protein kinase C signaling GO:0090037 9.65 FLT4 VEGFA
40 positive regulation of transforming growth factor beta production GO:0071636 9.65 CD34 THBS1
41 positive regulation of MAP kinase activity GO:0043406 9.65 FGF2 FLT1 KIT PDGFRB VEGFA
42 endothelium development GO:0003158 9.64 CD34 KDR
43 regulation of cGMP metabolic process GO:0030823 9.63 THBS1 VEGFA
44 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
45 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.61 PDGFRB VEGFA
46 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.6 ENG KIT
47 positive regulation of phospholipase C activity GO:0010863 9.26 FGF2 FLT1 KIT PDGFRB
48 positive regulation of angiogenesis GO:0045766 9.17 CD34 ENG FGF2 FLT1 KDR THBS1
49 phosphorylation GO:0016310 10.09 FLT1 FLT4 KDR KIT PDGFRB
50 protein phosphorylation GO:0006468 10.07 FLT1 FLT4 KDR KIT PDGFRB

Molecular functions related to Vascular Cancer according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 FLT1 FLT4 KDR KIT PDGFRB
2 protein kinase activity GO:0004672 9.77 FLT1 FLT4 KDR KIT PDGFRB
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.67 FGF2 KIT PDGFRB
4 integrin binding GO:0005178 9.61 KDR THBS1 VWF
5 transforming growth factor beta binding GO:0050431 9.51 ENG THBS1
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 FGF2 KIT PDGFRB
7 platelet-derived growth factor receptor binding GO:0005161 9.46 PDGFRB VEGFA
8 growth factor binding GO:0019838 9.43 FLT1 FLT4 KDR
9 protein tyrosine kinase activity GO:0004713 9.43 FGF2 FLT1 FLT4 KDR KIT PDGFRB
10 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 KDR KIT
11 vascular endothelial growth factor-activated receptor activity GO:0005021 9.33 FLT1 FLT4 KDR
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT PDGFRB

Sources for Vascular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....